March 6, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Natus Medical Inc (NASDAQ:BABY) shares over potential securities laws violations by Natus Medical and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Natus Medical Inc (NASDAQ:BABY) concerning whether a series of statements by Natus Medical Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Natus Medical Inc reported that its annual Total Revenue rose from $232.90 million in 2011 to $355.83 million in 2014 and that its Net Loss of $11.18 million in 2011 turned into a Net Income of $31.70 million in 2014. Shares of Natus Medical Inc (NASDAQ:BABY) grew from $743 per share in November 2011 to as high as $37.60 per share in January 2015.

Then on March 3, 2015, Natus Medical Inc disclosed that as of March 2, 2015, the filing deadline for its Annual Report for 2014, it had not yet completed the assessment of the Companys internal control over financial reporting. Natus Medical Inc said that it expects to report in the Annual Report for 2014 that as of December 31, 2014, a material weakness existed in its control over financial reporting due to an aggregation of control deficiencies resulting from a lack of timely risk assessment and monitoring of internal control over financial reporting to ensure the proper application of U.S. GAAP in certain areas.